

THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. *Lancet Oncol* 2021; published online April 1. [http://dx.doi.org/10.1016/S1470-2045\(21\)00155-8](http://dx.doi.org/10.1016/S1470-2045(21)00155-8).

Table 1: Characteristics of patients treated with immune-checkpoint inhibitors (ICI) and received two doses of the BNT162b2 mRNA Covid-19 vaccine

		N = 134 (%)
Median Age (range)		72 (29-93)
Gender	Male	73 (55)
	Female	61 (44)
Comorbidities	Diabetes	42 (30.8)
	Hypertension	81 (59.5)
	Obesity	32 (23.5)
	Dyslipidemia	59 (43.3)
	Smoking	39 (28.6)
Cancer type	Lung	66 (49.2)
	Genito-urinary	15 (11.2)
	Gastrointestinal	11 (8.2)
	Melanoma	16 (11.9)
	Others	26 (19.4)
Cancer Stage	Local	27 (20.2)
	Metastatic	107 (79.8)
Oncology treatment	ICI only	97 (72.4)
	ICI and chemotherapy	37 (27.6)
Previous immune-related side effects	Grade \geq 2	47 (35)
	Grade 0-1	87 (65)
Immunotherapy Treatment	Pembrolizumab	74 (55.2)
	Nivolumab	25 (18.6)
	Nivolumab +Ipilimumab	8 (5.9)
	Atezolizumab	3 (2.2)
	Durvalumab	15 (11.2)
	Cemiplimab	9 (6.7)
Time on ICI-treatment, Median (range) months	8.7 (1- 44)	

Table 2: Systemic Side Effects after second dose of vaccine

Side Effect	N=134 (%)
Fatigue	45 (34)
Headache	22 (16)
Muscle Pain	46 (34)
Fever	14 (10)
Chills	14 (10)
Flu like symptoms	3 (2.2)
GI Disturbance	14 (10)